Tvardi Therapeutics posts KOL webinar deck on TTI-109 potential in ulcerative colitis

Reuters2026/08/19 15:15

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Tvardi Therapeutics posted a medical research presentation outlining the rationale for STAT3 inhibition in ulcerative colitis using its oral STAT3 program.
Slides position TTI-109 as an oral prodrug of TTI-101, targeting STAT3 nuclear function as a convergent hub across inflammatory pathways.
Presentation highlights prior clinical observations for TTI-101, including reduced pY-STAT3 target engagement and declines in IL-6 and fibrosis measures.
Phase 1 multiple-ascending-dose data for TTI-109 showed placebo-adjusted reductions in STAT3-driven immune populations, including Th17, Tfh, and B cells.
Document also outlines a proposed proof-of-concept trial design for ulcerative colitis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tvardi Therapeutics Inc. published the original content used to generate this news brief on August 19, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Tvardi Therapeutics posts KOL webinar deck on TTI-109 potential in ulcerative colitis

You may also like

Crypto prices